The European Commission approved the tablet formulation of BRUKINSA, which is a key growth engine for BeOne Medicines.
3 reports, 2 independent
Updated Aug 22
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The European Commission approved the tablet formulation of BRUKINSA, which is a key growth engine for BeOne Medicines.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
BeOne Medicines (Switzerland)
company in Basel, Switzerland
Nothing else this week.
-
Europe
terrestrial continent located in north-western Eurasia
Coverage
Newest first; wire copies grouped- Simply Wall St.BRUKINSA Tablet Approval Could Be a Game Changer for BeOne Medicines (ONC) BeOne Medicines recently announced that the European Commission approved a new film-coated tablet formulation of BRUKINSA (z
- Business WireEuropean Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications Tablets will advance treatment simplicity and convenience to meet patient needs across Europ
- Business WireBeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates Second quarter total revenues increased 42% to $1.3 billion versus second quarter 2024 Global BRUKINSA revenues in